title: Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats.
abstract: Benign prostatic hyperplasia (BPH) is the most common age-related disease in men. Here we tested the efficacy of Rapatar, a micellar nanoformulation of rapamycin, in two rat models of BPH: testosterone-induced and sulpiride-induced hyperplasia in ventral lobes and lateral/dorsal lobes, respectively. We found that Rapatar prevented hypertrophic and hyperplastic abnormalities and degenerative alterations in both BPH models. Rapatar normalized weight of the lateral lobes in sulpiride-induced BPH, the most relevant animal model of human BPH. Unlike Finasteride, a standard therapy of BPH, Rapatar reduced inflammation caused by sulpiride. No obvious side effects of Rapatar were detected. Our data provide a rationale for clinical trials of Rapatar in patients suffering from BPH.
authors.affiliation: Department of Chemical Carcinogenesis, Blokhin Cancer Research Center, Moscow, Russia.
authors.forename: Ekaterina A
authors.initials: EA
authors.lastname: Lesovaya
authors.affiliation: Department of Chemical Carcinogenesis, Blokhin Cancer Research Center, Moscow, Russia.
authors.forename: Kirill I
authors.initials: KI
authors.lastname: Kirsanov
authors.affiliation: Department of Chemical Carcinogenesis, Blokhin Cancer Research Center, Moscow, Russia.
authors.forename: Elena E
authors.initials: EE
authors.lastname: Antoshina
authors.affiliation: Department of Chemical Carcinogenesis, Blokhin Cancer Research Center, Moscow, Russia.
authors.forename: Lubov S
authors.initials: LS
authors.lastname: Trukhanova
authors.affiliation: Department of Chemical Carcinogenesis, Blokhin Cancer Research Center, Moscow, Russia.
authors.forename: Tatiana G
authors.initials: TG
authors.lastname: Gorkova
authors.affiliation: Tartis-Aging LLC, Moscow, Russia.
authors.forename: Elena V
authors.initials: EV
authors.lastname: Shipaeva
authors.affiliation: Tartis-Aging LLC, Moscow, Russia.
authors.forename: Ramiz M
authors.initials: RM
authors.lastname: Salimov
authors.affiliation: Department of Chemical Carcinogenesis, Blokhin Cancer Research Center, Moscow, Russia.
authors.forename: Gennady A
authors.initials: GA
authors.lastname: Belitsky
authors.affiliation: Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY, USA.
authors.forename: Mikhail V
authors.initials: MV
authors.lastname: Blagosklonny
authors.affiliation: Department of Chemical Carcinogenesis, Blokhin Cancer Research Center, Moscow, Russia.
authors.forename: Marianna G
authors.initials: MG
authors.lastname: Yakubovskaya
authors.affiliation: Everon Biosciences, Inc., Buffalo, NY, USA.
authors.forename: Olga B
authors.initials: OB
authors.lastname: Chernova
mesh_terms: D000375:Aging; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000737:chemistry / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D018120:Finasteride / Q000627:therapeutic use; D008297:Male; D050997:Nanomedicine / Q000379:methods*; D011467:Prostate / Q000187:drug effects; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D051381:Rats; D017208:Rats, Wistar; D020123:Sirolimus / Q000737:chemistry / Q000627:therapeutic use; D013469:Sulpiride / Q000737:chemistry; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism; D013739:Testosterone / Q000737:chemistry
chemical_list: D000903:Antibiotics, Antineoplastic; D013739:Testosterone; D018120:Finasteride; D013469:Sulpiride; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus
keywords: aging; benign prostatic hyperplasia; gerotarget; mTOR; rapamycin